Efficacy and safety of an intravenous C1-inhibitor concentrate for long-term prophylaxis in hereditary angioedema

BACKGROUND: The plasma-derived, pasteurized, nanofiltered C1-inhibitor concentrate (pnfC1-INH) is approved in the United States as an intravenous (IV) on-demand treatment for hereditary angioedema (HAE) attacks, and, in Europe, as on demand and short-term prophylaxis. OBJECTIVE: This analysis evalua...

Descripción completa

Detalles Bibliográficos
Autores principales: Craig, Timothy, Shapiro, Ralph, Vegh, Arthur, Baker, James W., Bernstein, Jonathan A., Busse, Paula, Magerl, Markus, Martinez-Saguer, Inmaculada, Riedl, Marc A., Lumry, William, Williams-Herman, Debora, Edelman, Jonathan, Feuersenger, Henrike, Machnig, Thomas, Rojavin, Mikhail
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OceanSide Publications, Inc. 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5380447/
https://www.ncbi.nlm.nih.gov/pubmed/28381322
http://dx.doi.org/10.2500/ar.2017.8.0192

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5380447/
https://www.ncbi.nlm.nih.gov/pubmed/28381322
http://dx.doi.org/10.2500/ar.2017.8.0192

Ejemplares similares